<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575133</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1450</org_study_id>
    <nct_id>NCT00575133</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study in Patients With NAFLD</brief_title>
  <official_title>Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the importance of intracellular signalling pathways and its deregulation in&#xD;
      adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering&#xD;
      from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will&#xD;
      be analyzed prospectively from a liver tissue bank.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with suspected fatty liver disease will be screened (and excluded in the presence)&#xD;
      of alternative clinical condition associated with NAFLD (see exclusion criteria). Of all&#xD;
      patients fulfilling inclusion criteria, relevant baseline characteristics (incl.&#xD;
      epidemiological, physiological and biochemical data) will be obtained. In addition,&#xD;
      radiological examination will be performed using sonography and fibroscan to assess&#xD;
      non-invasively the individual extent of hepatic fat deposition, liver stiffness (fibrosis)&#xD;
      and amount of visceral fat mass. In case of high clinical, laboratory and radiological&#xD;
      suspicion for NAFLD, a diagnostic liver biopsy will be performed. A part of the liver tissue&#xD;
      is used for histological confirmation of NAFLD and subsequent grading and staging according&#xD;
      established criteria. Parts of the remaining liver tissue will be stored for later molecular&#xD;
      and histological analysis. In addition, several serum samples are collected of patients and&#xD;
      stored for future analysis. All patients will be followed up annually (incl. physical&#xD;
      examination, metabolic characterisation, clinical chemistry and liver sonography) and&#xD;
      additional serum samples will be collected for future analysis. Liver biopsy is not repeated&#xD;
      after defined time period, but in case of clinical evidence for disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease regression/progression</measure>
    <time_frame>20 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-alcoholic fatty liver disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed fatty liver disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of significant alcohol consumption&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Autoimmune hepatitis&#xD;
&#xD;
          -  Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)&#xD;
&#xD;
          -  Hepatotoxic medication (e.g. amiodarone).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giatgen Spinas, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Endocrinology and Diabetology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Tschopp</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>oliver.tschopp@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giatgen Spinas, Professor, MD</last_name>
    <email>giatgen.spinas@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Endocrinology and Diabetology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Tschopp, MD</last_name>
      <email>oliver.tschopp@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

